Table 1.
Baseline characteristics of the study cohort.
| Number of patients | 18 |
| Age (years) | 75.2 [68.4, 81] |
| Gender (% female) | 78 |
| Race - Black (%), White (%) | 11, 89 |
| Comorbidities | |
| History of Atrial Fibrillation or atrial flutter (%) | 56 |
| Hypertension (%) | 89 |
| Diabetes (%) | 33 |
| Coronary Artery Disease (%) | 39 |
| Previous Myocardial Infarction (%) | 0 |
| HF or HTN Medication | |
| Loop Diuretic (%) | 83 |
| ACE or ARB (%) | 33 |
| Beta-Blocker (%) | 56 |
| Mineralocorticoid receptor antagonist (%) | 67 |
| Calcium channel blocker (%) | 39 |
| Sacubitril/valsartan (%) | 6 |
| SGLT2 inhibitors | 17 |
| Biometrics | |
| Body mass index (kg/m2) | 35.3 [27.6, 37.2] |
| Left Ventricular Ejection Fraction (core lab measured) (%) | 61.0 [56.0-63.2] |
| NYHA Class II/III (%) | II: 5.6, III: 88.9, IV: 5.6 |
| Systolic Blood Pressure (mmHg) | 123.5 [114.5-135.8] |
| Diastolic Blood Pressure (mmHg) | 71.5 [66.2-78.8] |
| Resting Heart Rate (beats/min) | 73.5 (69.2-80.8) |
| NT-proBNP (pg/mL) | 334 [148, 698] |
| Creatinine (mg/dL) | 0.94 [0.9, 1.3] |
| Estimated glomerular filtration rate (ml/min/1.73 m2) | 60.5 (45.2-66.8) |
| Echocardiography | |
| Left Ventricular Ejection Fraction (core lab measured) (%) | 61.0 [56.0-63.2] |
| Left ventricular mass index (g/m2) | 80.5 [67.7-93.1] |
| LA end-diastolic volume index (mL/m2) | 19.4 [13.9-25.8] |
| LV end-diastolic volume index (mL/m2) | 40.4 [37.6-45.7] |
| E/e' (septal) (unitless) | 15.8 [11.3-21.8] |
| Mitral E velocity/Mitral A velocity (unitless) | 1.0 [0.8-1.8] |
| Baseline invasive exercise hemodynamics | |
| Resting PCWP (mmHg) | 17.0 [4.0-34.0] |
| Legs up PCWP (mmHg) | 24.0 [11.0-33.0] |
| 20W PCWP (mmHg) | 35.0 [22.0-50.0] |
| Peak PCWP (mmHg) | 37.0 [26.0-50.0] |
| Exercise duration (minutes) | 6.0 [4.0-9.0] |
| Peak workload (Watts) | 40.0 [20.0-60.0] |
Abbreviations: ACE =angiotensin converting enzyme; ARB = angiotensin receptor blocker; BMI=body mass index; CVP=central venous pressure; KCCQ=Kansas City Cardiomyopathy Questionnaire; LVEF=left ventricular ejection fraction; NT-proBNP=N terminal pro brain natriuretic peptide; NYHA=New York Heart Association; SGLT2 = sodium glucose like transporter 2; medians and interquartile range is provided unless otherwise specified.